Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies: Research report

Paola Penza, Angela Campanella, Alfredo Martini, Giorgia Melli, Raffaella Lombardi, Francesca Camozzi, Grazia Devigili, Giuseppe Lauria

Research output: Contribution to journalArticle

Abstract

Buprenorphine is a potent opioid available as a transdermal delivery system (TDS) formulation. This open-label study investigated its safety, tolerability, and efficacy in 30 patients with chronic painful neuropathy. Subjects with visual analogue scale (VAS) score ≥5 under stable analgesic treatment were entered. The starting dosage of 35 μg/h was increased up to 70.0 μg/h in case of unsatisfactory pain control as assessed by fortnightly visits. The primary endpoint was the number of patients achieving at least 30% pain relief at day 42 visit. Treatment was safe over the study period. Nine patients dropped out for side effects, mostly nausea and daily sleepiness. Buprenorphine TDS was well tolerated in 21 patients. Thirteen patients achieved >30% of pain relief at day 42 visit. Five patients needed to increase the dosage to 52.5 μg/h. Eight patients did not meet the primary outcome, but none allowed increasing the dosage to 70 μg/h, and four patients withdrew consent to continue the study before day 42 visit because of a 'fear to become addicted,' although 40% had obtained VAS reduction. In our study, which needs to be confirmed by a controlled trial, buprenorphine TDS induced clinically meaningful pain relief in about 40% of patients with chronic painful neuropathy, suggesting its use as a third-line treatment.

Original languageEnglish
Pages (from-to)283-288
Number of pages6
JournalJournal of the Peripheral Nervous System
Volume13
Issue number4
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Buprenorphine
Pain
Visual Analog Scale
Painful Neuropathy
Nausea
Opioid Analgesics
Fear
Analgesics
Therapeutics
Safety

Keywords

  • Buprenorphine
  • Nerve conduction studies
  • Neuropathic pain
  • Opioids
  • Pain relief
  • Painful neuropathy
  • Peripheral neuropathies
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies : Research report. / Penza, Paola; Campanella, Angela; Martini, Alfredo; Melli, Giorgia; Lombardi, Raffaella; Camozzi, Francesca; Devigili, Grazia; Lauria, Giuseppe.

In: Journal of the Peripheral Nervous System, Vol. 13, No. 4, 12.2008, p. 283-288.

Research output: Contribution to journalArticle

Penza, Paola ; Campanella, Angela ; Martini, Alfredo ; Melli, Giorgia ; Lombardi, Raffaella ; Camozzi, Francesca ; Devigili, Grazia ; Lauria, Giuseppe. / Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies : Research report. In: Journal of the Peripheral Nervous System. 2008 ; Vol. 13, No. 4. pp. 283-288.
@article{f7c4140bb86a4be7a9115f524521973d,
title = "Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies: Research report",
abstract = "Buprenorphine is a potent opioid available as a transdermal delivery system (TDS) formulation. This open-label study investigated its safety, tolerability, and efficacy in 30 patients with chronic painful neuropathy. Subjects with visual analogue scale (VAS) score ≥5 under stable analgesic treatment were entered. The starting dosage of 35 μg/h was increased up to 70.0 μg/h in case of unsatisfactory pain control as assessed by fortnightly visits. The primary endpoint was the number of patients achieving at least 30{\%} pain relief at day 42 visit. Treatment was safe over the study period. Nine patients dropped out for side effects, mostly nausea and daily sleepiness. Buprenorphine TDS was well tolerated in 21 patients. Thirteen patients achieved >30{\%} of pain relief at day 42 visit. Five patients needed to increase the dosage to 52.5 μg/h. Eight patients did not meet the primary outcome, but none allowed increasing the dosage to 70 μg/h, and four patients withdrew consent to continue the study before day 42 visit because of a 'fear to become addicted,' although 40{\%} had obtained VAS reduction. In our study, which needs to be confirmed by a controlled trial, buprenorphine TDS induced clinically meaningful pain relief in about 40{\%} of patients with chronic painful neuropathy, suggesting its use as a third-line treatment.",
keywords = "Buprenorphine, Nerve conduction studies, Neuropathic pain, Opioids, Pain relief, Painful neuropathy, Peripheral neuropathies, Treatment",
author = "Paola Penza and Angela Campanella and Alfredo Martini and Giorgia Melli and Raffaella Lombardi and Francesca Camozzi and Grazia Devigili and Giuseppe Lauria",
year = "2008",
month = "12",
doi = "10.1111/j.1529-8027.2008.00194.x",
language = "English",
volume = "13",
pages = "283--288",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies

T2 - Research report

AU - Penza, Paola

AU - Campanella, Angela

AU - Martini, Alfredo

AU - Melli, Giorgia

AU - Lombardi, Raffaella

AU - Camozzi, Francesca

AU - Devigili, Grazia

AU - Lauria, Giuseppe

PY - 2008/12

Y1 - 2008/12

N2 - Buprenorphine is a potent opioid available as a transdermal delivery system (TDS) formulation. This open-label study investigated its safety, tolerability, and efficacy in 30 patients with chronic painful neuropathy. Subjects with visual analogue scale (VAS) score ≥5 under stable analgesic treatment were entered. The starting dosage of 35 μg/h was increased up to 70.0 μg/h in case of unsatisfactory pain control as assessed by fortnightly visits. The primary endpoint was the number of patients achieving at least 30% pain relief at day 42 visit. Treatment was safe over the study period. Nine patients dropped out for side effects, mostly nausea and daily sleepiness. Buprenorphine TDS was well tolerated in 21 patients. Thirteen patients achieved >30% of pain relief at day 42 visit. Five patients needed to increase the dosage to 52.5 μg/h. Eight patients did not meet the primary outcome, but none allowed increasing the dosage to 70 μg/h, and four patients withdrew consent to continue the study before day 42 visit because of a 'fear to become addicted,' although 40% had obtained VAS reduction. In our study, which needs to be confirmed by a controlled trial, buprenorphine TDS induced clinically meaningful pain relief in about 40% of patients with chronic painful neuropathy, suggesting its use as a third-line treatment.

AB - Buprenorphine is a potent opioid available as a transdermal delivery system (TDS) formulation. This open-label study investigated its safety, tolerability, and efficacy in 30 patients with chronic painful neuropathy. Subjects with visual analogue scale (VAS) score ≥5 under stable analgesic treatment were entered. The starting dosage of 35 μg/h was increased up to 70.0 μg/h in case of unsatisfactory pain control as assessed by fortnightly visits. The primary endpoint was the number of patients achieving at least 30% pain relief at day 42 visit. Treatment was safe over the study period. Nine patients dropped out for side effects, mostly nausea and daily sleepiness. Buprenorphine TDS was well tolerated in 21 patients. Thirteen patients achieved >30% of pain relief at day 42 visit. Five patients needed to increase the dosage to 52.5 μg/h. Eight patients did not meet the primary outcome, but none allowed increasing the dosage to 70 μg/h, and four patients withdrew consent to continue the study before day 42 visit because of a 'fear to become addicted,' although 40% had obtained VAS reduction. In our study, which needs to be confirmed by a controlled trial, buprenorphine TDS induced clinically meaningful pain relief in about 40% of patients with chronic painful neuropathy, suggesting its use as a third-line treatment.

KW - Buprenorphine

KW - Nerve conduction studies

KW - Neuropathic pain

KW - Opioids

KW - Pain relief

KW - Painful neuropathy

KW - Peripheral neuropathies

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=58449114941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449114941&partnerID=8YFLogxK

U2 - 10.1111/j.1529-8027.2008.00194.x

DO - 10.1111/j.1529-8027.2008.00194.x

M3 - Article

C2 - 19192068

AN - SCOPUS:58449114941

VL - 13

SP - 283

EP - 288

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 4

ER -